Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.

Pheast Therapeutics

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

ADCs

Improved Efficacy and Safety Driving Resurging Interest in ADCs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Ovarian Cancer

Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Precision Medicine

What role is precision medicine playing in transforming cancer treatment — and how are developers adapting?

Pharma's Almanac

Pediatric Oncology

The Strategic Case for Investing in Pediatric Oncology, Beyond Altruism

Emilee Kudla

Pharma's Almanac

Pediatric Oncology

The "Therapeutic Winter" and Why Urgent Innovation in Pediatric Oncology Is Being Left Behind

Emilee Kudla

Pharma's Almanac

Pediatric Cancer

Bridging the Gap in Pediatric Cancer Access...A Call to Investors and Pharma Leaders

Emilee Kudla; David Alvaro, Ph.D.

Pharma's Almanac

Oncology

Engineered Bacteria as Precision Therapeutics for Cancer and Beyond

David Alvaro, Ph.D.

Pharma's Almanac

Exosomes

Nature’s Nanocarriers: The Evolving Role of Exosomes in Targeted Drug Delivery

David Alvaro, Ph.D.

Pharma's Almanac